Pleased to share our latest work, published today in @ESMO_Open 👇
As HER-targeted ADCs continue to evolve, understanding HER1–HER4 co-expression may help inform future drug development and patient selection.
sciencedirect.com/science/ar…@OncoAlert
🧵Key findings:
That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup.
Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️
Can patients with muscle-invasive bladder cancer avoid radical cystectomy?
From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸
Listen to the full discussion ⬇️
🎧 Apple: apple.co/4t9r8Ps
🎧 Spotify: bit.ly/4iPpf6Q
Impressive continuity (500+!) and outstanding quality for this podcast — which is supposed to be Uro-focused, but from which there’s actually a lot to learn across disease areas. Congrats!! @tompowles1@brian_rini
Thoughtful debate and banter on the latest in GU cancers for @uromigos. Palpable excitement on how far we’ve come in GU cancers. The livestream is available — Tune in wherever you are!
New @Annals_Oncology study exploring ctDNA-guided pembro in resected dMMR tumours.
- 92% 2-year RFS in MRD- without treatment
- Despite ⬆️clearance in treated MRD+, 38% relapsed. Sustained clearance may be more informative
@OncoAlert@YJanjigianMDannalsofoncology.org/article…
That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup.
Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️
The OncoAlert 🚨 Coverage of #UromigosLIVE 🎸 2026
ctDNA: can we spare adjuvant EV?
Dr. Jonathan Rosenberg 🇺🇸 @DrRosenbergMSK of @MSKCancerCenter discusses with Dr. Michiel van der Heijden🇳🇱 @MichvdHeijden of @NKI_nl on how he uses ctDNA in MIBC today:
🔹 Mostly post-op, based on IMvigor011: it helps risk-stratify patients, especially after an excellent pathologic response to neoadjuvant therapy
🔹 Rising ctDNA before surgery is a very bad sign. Consider other approaches before cystectomy
🔹 Clear before surgery, negative after and staying negative: these patients do really, really well
🔹 Bladder preservation cuts both ways. Persistently positive patients likely fail distantly, but some clear their ctDNA with surgery. Would they also clear with chemoradiation or more EV-P? EV-209, EV-309 and sac-TMT + pembro trials should help answer this
🔹 ctDNA down but not cleared → go to surgery, then continue adjuvant therapy
💬 "Surgery is curing patients. It's just not curing all patients."
💡 After VOLGA, he's more likely to drop adjuvant EV: great neoadjuvant response + ctDNA-negative after surgery → most are probably cured. Less EV means less toxicity, and some of it is long-term.
Would you de-escalate adjuvant EV based on ctDNA?
👇 #BladderCancer#MIBC#ctDNA#GUOnc@Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan
⭐🟢 #UromigosLive 2026 | Nashville 🎸
🚨 ENGANCHADORES DE CÉLULAS T EN CÁNCER RENAL: ¿Estamos ante un nuevo paradigma?
🔬 XmAb819, anticuerpo biespecífico ENPP3 × CD3, busca redirigir los linfocitos T contra las células tumorales.
📊 Resultados preliminares fase I:
✅ Respuesta objetiva confirmada: 45,5% con 400 μg/kg (n=11).
✅ SLP estimada a 6 meses: 82%.
✅ Actividad prometedora en pacientes previamente tratados.
⚠️ La toxicidad sigue siendo un desafío: síndrome de liberación de citocinas, especialmente durante la fase inicial del tratamiento.
💡 Mensaje clínico: La redirección de células T podría ampliar las opciones terapéuticas en cáncer renal refractario.
Todavía necesitamos confirmar eficacia, duración de respuesta y seguridad en estudios de mayor tamaño.
🎙️ Excelente debate con Brian Rini, Monty Pal, Hans Hammers, David McDermott y James Larkin.
@Uromigos@OncoAlert@tompowles1@brian_rini@montypal@HHammersMD@MVossMD@TiansterZhang@AlbigesL#CancerRenal#OncologiaGU#GUOncology#Inmunoterapia
Bladder cancer ph2 trial concept ADAPT-MIBC @SuzanneColeMD@PGrivasMDPhD
👥 pts ctDNA+ after EV/IO & switch therapies BEFORE cystectomy or chemo-RT OR observation until they are (-)
➡️ goal to avoid interruption in systemic therapy for ctDNA+ pts
#UromigosLive@OncoAlert
⭐🟢 #UromigosLive 2026 🎸 | Nashville
🔬 PEAK-20: ¿UNA NUEVA GENERACIÓN DE TRIPLETES EN CÁNCER RENAL METASTÁSICO?
🔥 ¡Continúa el debate sobre el futuro del tratamiento de primera línea!
Tras los resultados decepcionantes de diferentes estrategias triples, PEAK-20 propone una nueva combinación basada en la inhibición de HIF-2α.
📊 PEAK-20 | Fase III | N previsto=660
✅ Casdatifan + nivolumab + ipilimumab frente a nivolumab + ipilimumab.
✅ Pacientes con carcinoma renal de células claras avanzado o metastásico, sin tratamiento sistémico previo para enfermedad metastásica.
✅ Incluye todos los grupos de riesgo IMDC.
🎯 Objetivo primario: supervivencia libre de progresión.
🔬 Objetivos secundarios: supervivencia global, respuesta objetiva, duración de respuesta, control de enfermedad y seguridad.
💡 Reflexión clínica: No se trata simplemente de sumar un tercer fármaco, sino de incorporar un mecanismo de acción diferente que pueda mejorar los resultados manteniendo una toxicidad aceptable.
⚠️ El estudio está planificado y todavía debe demostrar su beneficio clínico.
🎸 ¡Excelente intercambio científico y nuevas preguntas para la investigación en cáncer renal!
@LosUromigos@Uromigos@tompowles1@brian_rini@OncoAlert@montypal@HHammersMD@AlbigesL@MVossMD@TiansterZhang@ViktorGruenwald@nataliagandur@weoncologists#UromigosLive#CancerRenal#KidneyCancer#RCC#OncologiaGU#InvestigacionClinica
There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1@shilpaonc@MichvdHeijden@kalasri3@DrRosenbergMSK@MattGalsky@PGrivasMDPhD@JoshMeeks Anna Wilkins
Rough conclusion from #UromigosLive :
👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden
👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK
👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc
👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors.
👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD
👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky
👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1